Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 105

Sort by

Sort Order Select

Journal Articles

A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

Blood (2024) 144 (18): 1951–1961.

https://doi.org/10.1182/blood.2024024761

Published: 2024

Includes: Supplemental data

Journal Articles

Blood Basophil Concentration at Diagnosis Corelates with Prognosis in Newly-Diagnosed Persons with Chronic Myeloid Leukaemia

Lucia Vrablova, Xiaoshuai Zhang, Eva Kriegova, Milos Kudelka, Martin Radvansky, Sen Yang, Jaroslava Juranova, Tomas Papajik, Robert Peter Gale, Qian Jiang, Edgar Faber

Blood (2023) 142 (Supplement 1): 6374.

https://doi.org/10.1182/blood-2023-187548

Published: 2023

Journal Articles

FLT3-ITD Induces Immune Escape in AML Via up-Regulating CD47 Expression and Decreased Phagocytic Ability of Macrophages

Yun Wang, Shuzhao Chen, Limei Zhang, Jiangtao Song, Huaze Liao, Mayan Huang, Kunying Xie, Robert Peter Gale, Yang Liang

Blood (2023) 142 (Supplement 1): 2962.

https://doi.org/10.1182/blood-2023-190969

Published: 2023

Journal Articles

Single Cell Analyses Indicate SRSF2 and TET2 Co-Mutation Results in Skewed Haematopoiesis in Myelodysplastic Syndromes

Fang Hu, Xiaojin Li, Robert Peter Gale, Suning Chen, Yang Liang

Blood (2023) 142 (Supplement 1): 1848.

https://doi.org/10.1182/blood-2023-184508

Published: 2023

Journal Articles

3rd-Generation Tyrosine Kinase-Inhibitors and Azacitidine Are Safe and Effective in Myeloid Blast-Phase Chronic Myeloid Leukaemia and Result in a High Proportion of Subjects in 2 nd Chronic Phase Able to Receive a Transplant

Mei Bao, Xiang Wang, Xiao-shuai Zhang, Zong-ru Li, Robert Peter Gale, Xiao-jun Huang, Qian Jiang

Blood (2023) 142 (Supplement 1): 4550.

https://doi.org/10.1182/blood-2023-185346

Published: 2023

Journal Articles

Comparison of the 2022 ICC and Who Classification Systems of Myelodysplastic Neoplasms

Junying Wu, Yudi Zhang, Tiejun Qin, Zefeng Xu, Shiqiang Qu, Li Juan Pan, Robert Peter Gale, Bing Li, Zhijian Xiao

Blood (2023) 142 (Supplement 1): 1875.

https://doi.org/10.1182/blood-2023-184604

Published: 2023

Journal Articles

Is the Prognosis of People with Chronic Myeloid Leukaemia Presenting in Accelerated Phase Always Worse Compared with People Presenting in Chronic Phase?

Sen Yang, Xiaoshuai Zhang, Mengyu Zhang, Robert Peter Gale, Xiao Jun Huang, Qian Jiang

Blood (2023) 142 (Supplement 1): 1804.

https://doi.org/10.1182/blood-2023-184568

Published: 2023

Journal Articles

Validation and Use of Predictive Scoring Systems for Molecular Responses in 5,203 Persons with Chronic Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 9620–9623.

https://doi.org/10.1182/blood-2022-166431

Published: 2022

Journal Articles

A Predictive Scoring System for Therapy Failure in Persons with Chronic Myeloid Leukemia Receiving Initial a Second-Generation Tyrosine Kinase Inhibitor Therapy

Blood (2022) 140 (Supplement 1): 9637–9639.

https://doi.org/10.1182/blood-2022-168703

Published: 2022

Journal Articles

Predicting Survival of Persons with Newly-Diagnosed Plasma Cell Myeloma

Limei Zhang, Yun Wang, Robert Peter Gale, Yang Liang

Blood (2022) 140 (Supplement 1): 10088–10089.

https://doi.org/10.1182/blood-2022-166634

Published: 2022

Journal Articles

Subjects with Chronic Myeloid Leukemia Identified As Intermediate- or High-Risk Subjects Using the Imatinib Therapy Failure (IMTF) Model Benefit from Initial Therapy with a Second-Generation Tyrosine Kinase Inhibitor

Blood (2022) 140 (Supplement 1): 3891–3894.

https://doi.org/10.1182/blood-2022-168812

Published: 2022

Journal Articles

Why Don't Asians Get Chronic Lymphocytic Leukaemia? It's in Their Genes

Shenmiao Yang, Dan Liu, Wenbing Liu, Xiaojun Huang, Qian-fei Wang, Robert Peter Gale

Blood (2022) 140 (Supplement 1): 12365–12366.

https://doi.org/10.1182/blood-2022-165042

Published: 2022

Journal Articles

Validation of the 5 th Edition of the World Health Organization Classification of Myelodysplastic Neoplasms on 852 Consecutive De Novo Patients from a Single Institute

Yudi Zhang, Junying Wu, Tiejun Qin, Zefeng Xu, Shiqiang Qu, Lijuan Pan, Bing Li, Huijun Wang, Xin Yan, Jingye Gong, Robert Peter Gale, Zhijian Xiao

Blood (2022) 140 (Supplement 1): 1343–1345.

https://doi.org/10.1182/blood-2022-160131

Published: 2022

Journal Articles

Micheliolide Exerts Therapeutic Effect in Myeloproliferative Neoplasms through Binding to STAT3 and STAT5 Proteins and Inhibiting Their Activities

Huijun Huang, Jinqin Liu, Lin Yang, Yue Chen, Robert Peter Gale, Zhijian Xiao

Blood (2022) 140 (Supplement 1): 3065–3066.

https://doi.org/10.1182/blood-2022-165225

Published: 2022

Journal Articles

IPSS-M Is More Powerful for MDS Patients Older Than 60 Years Old

Junying Wu, Yudi Zhang, Tiejun Qin, Zefeng Xu, Shiqiang Qu, Lijuan Pan, Bing Li, Qingyan Gao, Robert Peter Gale, Zhijian Xiao

Blood (2022) 140 (Supplement 1): 4092–4093.

https://doi.org/10.1182/blood-2022-165083

Published: 2022

Journal Articles

Unique Clinical Features and Mutation Profile in De Novo Myelodysplastic Syndromes with MF-1 and a Proposed Model for Distinguishing MDS with MF-2/3 from TN-PMF Based on Clinical and Genetic Covariates

Junying Wu, Wenjun Zhang, Peihong Zhang, Tiejun Qin, Zefeng Xu, Qi Sun, Yujiao Jia, Shiqiang Qu, Bing Li, Huijun Wang, Lijuan Pan, Jinqin Liu, Yudi Zhang, Xin Yan, Robert Peter Gale, Zhijian Xiao

Blood (2022) 140 (Supplement 1): 4058–4059.

https://doi.org/10.1182/blood-2022-163019

Published: 2022

Journal Articles

Survival Prediction Optimization of Acute Myeloid Leukemia Based on T-Cell Function-Related Genes and Plasma Proteins

Shuzhao Chen, Yun Wang, Peidong Chi, Runcong Nie, Robert Peter Gale, Hanying Huang, Zhigang Chen, Yanyu Cai, Enping Yan, Na Zhong, Xinmei Zhang, Yang Liang

Blood (2022) 140 (Supplement 1): 6300–6302.

https://doi.org/10.1182/blood-2022-163201

Published: 2022

Journal Articles

Cancer-Related Gene Mutations Drive Resistance to the Third-Generation Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia

Xiaoshuai Zhang, Zongru Li, Ya-Zhen Qin, Robert Peter Gale, Yueyun Lai, Hongxia Shi, Xiao Jun Huang, Qian Jiang

Blood (2022) 140 (Supplement 1): 9611–9613.

https://doi.org/10.1182/blood-2022-169397

Published: 2022

Journal Articles

Correlations between Mutations in Cancer-Related Genes, Therapy Responses and Outcomes of the 3 rd Generation Tyrosine Kinase-Inhibitor (TKI) in Persons with Chronic Myeloid Leukemia Failing Prior TKI-Therapy

Xiaoshuai Zhang, Zongru Li, Yazhen Qin, Robert Peter Gale, Xiaojun Huang, Qian Jiang

Blood (2021) 138 (Supplement 1): 308.

https://doi.org/10.1182/blood-2021-150020

Published: 2021

Journal Articles

A Predictive Score for Failure-Free Survival in Persons with Chronic Myeloid Leukemia Receiving Imatinib

Xiaoshuai Zhang, Xiaojun Huang, Robert Peter Gale, Qian Jiang

Blood (2021) 138 (Supplement 1): 632.

https://doi.org/10.1182/blood-2021-146917

Published: 2021

NARROW

A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

Blood Basophil Concentration at Diagnosis Corelates with Prognosis in Newly-Diagnosed Persons with Chronic Myeloid Leukaemia

FLT3-ITD Induces Immune Escape in AML Via up-Regulating CD47 Expression and Decreased Phagocytic Ability of Macrophages

Single Cell Analyses Indicate SRSF2 and TET2 Co-Mutation Results in Skewed Haematopoiesis in Myelodysplastic Syndromes

3rd-Generation Tyrosine Kinase-Inhibitors and Azacitidine Are Safe and Effective in Myeloid Blast-Phase Chronic Myeloid Leukaemia and Result in a High Proportion of Subjects in 2 nd Chronic Phase Able to Receive a Transplant

Comparison of the 2022 ICC and Who Classification Systems of Myelodysplastic Neoplasms

Is the Prognosis of People with Chronic Myeloid Leukaemia Presenting in Accelerated Phase Always Worse Compared with People Presenting in Chronic Phase?

Validation and Use of Predictive Scoring Systems for Molecular Responses in 5,203 Persons with Chronic Myeloid Leukemia

A Predictive Scoring System for Therapy Failure in Persons with Chronic Myeloid Leukemia Receiving Initial a Second-Generation Tyrosine Kinase Inhibitor Therapy

Predicting Survival of Persons with Newly-Diagnosed Plasma Cell Myeloma

Subjects with Chronic Myeloid Leukemia Identified As Intermediate- or High-Risk Subjects Using the Imatinib Therapy Failure (IMTF) Model Benefit from Initial Therapy with a Second-Generation Tyrosine Kinase Inhibitor

Why Don't Asians Get Chronic Lymphocytic Leukaemia? It's in Their Genes

Validation of the 5 th Edition of the World Health Organization Classification of Myelodysplastic Neoplasms on 852 Consecutive De Novo Patients from a Single Institute

Micheliolide Exerts Therapeutic Effect in Myeloproliferative Neoplasms through Binding to STAT3 and STAT5 Proteins and Inhibiting Their Activities

IPSS-M Is More Powerful for MDS Patients Older Than 60 Years Old

Unique Clinical Features and Mutation Profile in De Novo Myelodysplastic Syndromes with MF-1 and a Proposed Model for Distinguishing MDS with MF-2/3 from TN-PMF Based on Clinical and Genetic Covariates

Survival Prediction Optimization of Acute Myeloid Leukemia Based on T-Cell Function-Related Genes and Plasma Proteins

Cancer-Related Gene Mutations Drive Resistance to the Third-Generation Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia

Correlations between Mutations in Cancer-Related Genes, Therapy Responses and Outcomes of the 3 rd Generation Tyrosine Kinase-Inhibitor (TKI) in Persons with Chronic Myeloid Leukemia Failing Prior TKI-Therapy

A Predictive Score for Failure-Free Survival in Persons with Chronic Myeloid Leukemia Receiving Imatinib

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only